

<b>Appendix 10 (as supplied by the authors): Results of threshold analysis on the cost of interferon-free antiviral therapy</b>			
<b><u>Age ranges</u></b>	<b><u>Strategies</u></b>	<b><u><math>\lambda</math>=\$50,000</u> <u>(ICER versus no screening)</u></b>	<b><u><math>\lambda</math>=\$100,000</u> <u>(ICER versus no screening)</u></b>
25-34	No screening	-	-
	Screen & treat with G1: IFN-Free DAA G2/3: SOF/RBV G4/5/6: PR	\$133,220	\$369,577
35-44	No screening	-	-
	Screen & treat with G1: IFN-Free DAA G2/3: SOF/RBV G4/5/6: PR	\$117,324	\$331,607
45-54	No screening	-	-
	Screen & treat with G1: IFN-Free DAA G2/3: SOF/RBV G4/5/6: PR	\$116,636	\$309,603
55-64	No screening	-	-
	Screen & treat with G1: IFN-Free DAA G2/3: SOF/RBV G4/5/6: PR	\$80,501	\$230,433
25-64	No screening	-	-
	Screen & treat with G1: IFN-Free DAA G2/3: SOF/RBV G4/5/6: PR	\$112,145	\$310,262
45-64	No screening	-	-
	Screen & treat with G1: IFN-Free DAA G2/3: SOF/RBV G4/5/6: PR	\$100,316	\$273,847
G1: genotype 1; G2/3: genotype 2 or 3; G4/5/6: genotype 4 or 5 or 6; PR = pegylated interferon plus ribavirin; SOF/RBV = sofosbuvir plus ribavirin; IFN-Free DAA = interferon-free direct-acting antiviral agents; ICER = incremental cost-effectiveness ratio			